Oligosaccharide Compositions for Gut Microbiome Ammonia Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Excessive ammonia accumulation in the gut due to microbial activity leads to elevated ammonia levels in hyperammonemic patients, which can cause health issues such as urea cycle disorders and hepatic encephalopathy.
Innovation Solution
Utilization of oligosaccharide compositions comprising specific oligosaccharides, characterized by a multiplicity-edited gradient-enhanced 1H-13C heteronuclear single quantum coherence (HSQC) NMR spectrum, to modulate the gut microbiome and reduce ammonia levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oligosaccharide compositions are administered to reduce ammonia levels, then ammonia reduction effectiveness is improved, but treatment cost and complexity increase
Solution Approach 1:
The patent employs specific oligosaccharide structures with defined molecular weights (500-5000 Da), degree of polymerization (2-20 units), and compositional ratios (e.g., galactose:glucose = 1:4 to 4:1) to optimize ammonia reduction. These parameter specifications ensure reliable therapeutic effect while providing clear formulation guidelines that reduce treatment complexity through standardization.
Solution Approach 2:
The invention uses composite oligosaccharide compositions containing multiple sugar types (galactose, glucose, mannose, fructose, xylose) in specific ratios rather than single compounds. This composite approach enhances ammonia reduction effectiveness through synergistic microbial metabolism while the defined composition ranges simplify manufacturing and dosing protocols.
2Reliability
If specific oligosaccharide compositions with defined structures are used, then therapeutic effectiveness is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent defines specific parameter ranges for oligosaccharide formulations including molecular weight (500-5000 Da), degree of polymerization (2-20), and monosaccharide composition ratios. These parameters balance therapeutic effectiveness with manufacturability by providing achievable specification ranges rather than requiring absolute precision.
Solution Approach 2:
The invention specifies particular structural features at different levels: overall composition ratios (e.g., galactose:glucose = 1:4 to 4:1), molecular weight distribution, and degree of polymerization. This hierarchical quality specification ensures critical therapeutic properties are controlled while allowing flexibility in less critical parameters, reducing manufacturing burden.
Data Source
AI summary
Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).